Business
New to The Street Announces Episodes 510 and 511 Six Corporate Interviews, airings on Newsmax and FOX Business Network, Broadcastings Begin Saturday, September 16, 2023, at 3:30 PM ET
New to The Street Announces Episodes 510 and 511 Six Corporate Interviews, airings on Newsmax and FOX Business Network, Broadcastings Begin Saturday, September 16, 2023, at 3:30 PM ET.
About this update from Sustainable Green Team, Ltd.
[{"type":"text","content":"\n NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces their corporate interviews for episodes 510 and 511 that will air on Newsmax and the FOX Business Network. New to The Street airs on Newsmax, Episode 510, on Saturday, September 16, 2023, at 3:30 PM ET, and the FOX Business Network, Episode 511, on Monday, September 18, 2023, at 10:30 PM PT, featuring the following Six Corporate interviews: 1). Biopharmaceutical - Tonix Pharmaceuticals, Inc.'s (NASDAQ: TNXP) ($TNXP) interview with Dr. Seth Lederman, MD, and CEO. 2). Weight Loss Solutions – SimpleMD's interviews with Dr. Ari Stoffer, MD, Founder and CEO. 3). Tax-Free Retirement – Kohler Tax Associates' interview with Mark Kohler, M.PR.A., CPA, JD, and Founder. 4). Gold/Silver Mining – Lahontan Gold Corp.'s (OTCQB: LGCXF) (TSXV: LG) ($LGCXF) interview with Kimberly Ann, Founder, CEO, President, and Director. 5). Sustainable Solutions - The Sustainable Green Team, Ltd.'s (OTCQX: SGTM) ($SGTM) interview with Brian Rivera, Director of Administration, and Brian Meier, Chief Operating Officer. 6). \"Sekur Privacy & Sekur Security Segment – The Weekly Hack\" interview with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®). Dr. Seth Lederman, MD, CEO of Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) (\"Tonix\"), talks with New to The Street's TV Host Jane King about the Company's progress on a treatment for Long-Covid. Dr. Lederman tells viewers that data from its FDA Phase 2 proof-of-concept PREVAIL study of TNX-102 SL shows top-line results in combating fatigue. Millions of Americans are experiencing fatigue issues from their COVID-19 infections. The Company needs more studies to bring the product to market once it obtains regulatory guidelines. US FDA and Health and Human Services (HHS) are looking into regulatory fast-track options, which are a must to bring products like TNXP's TNX-102 SL Long-Covid to market sooner, helping many overcome the fatigue onsets. Once FDA-approved, many patients with fatigue associated with Long-COVID will benefit from a comprehensive treatment. Tonix Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical Company that aims to improve health by innovating vaccines and therapies. The on-scree...